Cogent Biosciences, Inc., a biotechnology firm centered on creating precision therapies for genetically outlined ailments, has introduced the pricing of an underwritten public providing of 10,256,411 shares of its frequent inventory, provided at a public providing value of US$9.75 per share. In addition, Cogent Biosciences has granted the underwriters a 30-day choice to buy as much as a further 1,538,461 shares of its frequent inventory on the public providing value much less underwriting reductions. The dimension of the providing was upsized from US$60 million to roughly US$100 million. All of the shares of frequent inventory bought within the providing are being bought by Cogent Biosciences. The providing is predicted to shut on or about December 4, 2020, topic to customary closing circumstances.
Latham & Watkins LLP represented the underwriters within the providing with a capital markets workforce led by New York accomplice Nathan Ajiashvili, with New York associates Roger Yarett, Victoria McGrath, and Isabelle Sawhney.
Do you want Legal Desire’s articles? Follow on social!
